Do People with Work-Related Asthma Get Properly Vaccinated?
Adults with asthma are at increased risk for pneumococcal diseases, which are caused by the bacteria Streptococcus pneumoniae. These diseases include things like pneumonia, meningitis, and sepsis. Luckily, there are pneumococcal vaccines that can be delivered via simple injections under the skin or into the muscle that can potentially prevent these diseases.
The Centers for Disease Control and Prevention (CDC) recommends that all adults between the ages of 19 and 64 who suffer from asthma get the pneumococcal vaccine and that those older than 65 get 2 such vaccines. Nonetheless, according to a new study published in the American Journal of Preventative Medicine at the end of September, only about 50% of those with work-related asthma get the vaccine.
The study aimed to determine what percentage of people with different types of asthma actually get the pneumococcal vaccine as recommended. They were particularly interested in the difference between those with work-related asthma and those whose asthma occur independent of their work. The researchers analyzed national data from the years 2012 and 2013 and found that while overall, adults with asthma got the vaccine at a rate of about 50%. However, the likelihood of getting the vaccine varied depending on various factors. For instance, compared to those with work-related asthma, patients with asthma that was not work-related were less likely to get the pneumococcal vaccine. About 35% of those with asthma that was not work-related got the vaccine in 2012-2013.
The lowest rate of pneumococcal vaccination in work-related asthma patients was amongst Hispanics. Only about 36% of Hispanics with work-related asthma had gotten the vaccine. Uninsured patients and younger adults (ages 18-44) with work-related asthma also had low rates of vaccination, with only about 39% and 42% getting vaccinated, respectively.
Physicians and researchers are eager to get those with asthma to get the pneumococcal vaccine. The vaccination is important not only because pneumococcal diseases can be fatal (about 5-7% of the 900,000 Americans who get pneumococcal pneumonia each year die from it), but also because pneumococcal pneumonia can exacerbate asthma. Those with asthma are also at a higher risk for other complications related to pneumococcal disease.
Research like the current study that helps to reveal the actual uptake of the pneumococcal vaccine can be used to help physicians recognize the need to educate their asthma patients on the importance of the vaccine. Future studies may also be able to help clarify the best ways to increase compliance with the vaccine recommendation.